FIELD: medicine.
SUBSTANCE: what is produced is a recombinant protein created by gene shuffling possessing higher antiviral and antiproliferative activities as compared with existing human interferon-alpha-2b (HulFN-α2b). The prepared polypeptide is used in a composition as an antiviral, antiproliferative, anticancer or immunomodulatory agent.
EFFECT: invention enables using the prepared high-active interferon-like protein for treating a condition sensitive to interferon therapy, cancer or viral disease.
49 cl, 9 dwg, 8 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
POLYPEPTIDE WITH ANTIVIRAL, ANTIPROLIFERATIVE AND/OR IMMUNOMODULATING ACTIVITIES, SEPARATED POLYNUCLEOTIDE | 2002 |
|
RU2328528C2 |
RECOMBINANT CHIMERIC PROTEIN ANTH1, NUCLEIC ACID ENCODING ITS AND THEIR USING | 2003 |
|
RU2322455C2 |
INTERFERON-LIKE PROTEIN ZCYTO21 | 2001 |
|
RU2292394C2 |
ANTIBODIES RAISED AGAINST α-INTERFERON | 2002 |
|
RU2314317C2 |
HUMANISED NEUTRALIZING ANTIBODY TO HUMAN INTERFERON-BETA | 2019 |
|
RU2737466C1 |
FUSED PROTEIN ELICITING BIOLOGICAL ACTIVITY OF INTERFERON-ALPHA, DIMERIC FUSED PROTEIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF, DNA MOLECULE (VARIANTS) AND METHOD FOR TARGETING INTERFERON-ALPHA INTO LIVER TISSUE | 2000 |
|
RU2262510C9 |
STRAIN OF BACTERIA ESCHERICHIA COLI - PRODUCER OF RECOMBINANT PROTEIN NS1 | 2021 |
|
RU2789735C1 |
MONOCLONAL ANTIBODY CAPABLE OF NEUTRALIZING BIOLOGICAL ACTIVITY OF HUMAN INTERFERON BETA 1A | 2018 |
|
RU2729391C2 |
NOVEL AVIAN CYTOKINES AND GENETIC SEQUENCES CODING THEREOF | 2008 |
|
RU2562108C2 |
MONOCLONAL ANTIBODIES AGAINST INTERFERON-ALPHA AND APPLICATION METHODS | 2006 |
|
RU2431638C2 |
Authors
Dates
2012-12-10—Published
2007-06-22—Filed